Eribulin as First-Line Therapy for Metastatic HER2-Negative Breast Cancer
Joyce A. O’Shaughnessy, MD, from Baylor Charles A. Sammons Cancer Center, discusses the results of a recent breast cancer study.
Clinical Pearls
Joyce A. O’Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center; Texas Oncology, PA/US Oncology, Dallas, Texas, discusses the results of a recent breast cancer study.
- This study looked at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
- Overall response rate was 29%.
- Clinical benefit rate was 52%.
- Median PFS was 6.8 months.
- Responses were seen regardless of ER status.
Recent Videos
Related Content
Adjuvant T-DM1 Outperforms Trastuzumab in HER2-Positive Early Breast Cancer
February 12th 2025Article
Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease after neoadjuvant therapy.
Read More
